Syncom Formulations (India) Limited (NSE:SYNCOMF) — Market Cap & Net Worth
Market Cap & Net Worth: Syncom Formulations (India) Limited (SYNCOMF)
Syncom Formulations (India) Limited (NSE:SYNCOMF) has a market capitalization of $147.10 Million (Rs13.60 Billion) as of June 16, 2026. Listed on the NSE stock exchange, this India-based company holds position #17825 globally and #929 in its home market, demonstrating a -0.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syncom Formulations (India) Limited's stock price Rs14.47 by its total outstanding shares 940000000 (940.00 Million). Review SYNCOMF liabilities breakdown to assess the company's total debt and financial obligations.
Syncom Formulations (India) Limited Market Cap History: 2022 to 2026
Syncom Formulations (India) Limited's market capitalization history from 2022 to 2026. Data shows growth from $89.97 Million to $147.10 Million (17.62% CAGR).
Syncom Formulations (India) Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syncom Formulations (India) Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Syncom Formulations (India) Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.29x
Syncom Formulations (India) Limited's market cap is 0.29 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $89.97 Million | $2.18 Billion | $197.90 Million | 0.04x | 0.45x |
| 2023 | $152.99 Million | $2.24 Billion | $200.71 Million | 0.07x | 0.76x |
| 2024 | $203.31 Million | $2.63 Billion | $253.14 Million | 0.08x | 0.80x |
| 2025 | $144.96 Million | $4.65 Billion | $494.35 Million | 0.03x | 0.29x |
Competitor Companies of SYNCOMF by Market Capitalization
Companies near Syncom Formulations (India) Limited in the global market cap rankings as of June 16, 2026.
Key companies related to Syncom Formulations (India) Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Syncom Formulations (India) Limited Historical Marketcap From 2022 to 2026
Between 2022 and today, Syncom Formulations (India) Limited's market cap moved from $89.97 Million to $ 147.10 Million, with a yearly change of 17.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs147.10 Million | +1.47% |
| 2025 | Rs144.96 Million | -28.70% |
| 2024 | Rs203.31 Million | +32.89% |
| 2023 | Rs152.99 Million | +70.06% |
| 2022 | Rs89.97 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Syncom Formulations (India) Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $147.10 Million USD |
| MoneyControl | $147.10 Million USD |
| MarketWatch | $147.10 Million USD |
| marketcap.company | $147.10 Million USD |
| Reuters | $147.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more